Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Executive Summary
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
You may also be interested in...
GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
Sumitomo, Otsuka Both Stand To Gain From CNS Partnership
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.